肠道菌树突状细胞疫苗免疫疗法治疗胰腺癌的研究进展  

Research Progress of Intestinal Bacteria Dendritic Cell Vaccine Immunotherapy in the Treatment of Pancreatic Cancer

作　　者：李凯 黄海溶[2] 孙早喜[1] LI Kai;HUANG Hai-rong;SUN Zao-xi(Department of Hepatobiliary Surgery,First Affiliated Hospital of Hainan Medical University,Haikou,Hainan,570102,China)

机构地区：[1]海南医学院第一附属医院肝胆外科,海南海口570102 [2]海南医学院公共卫生学院,海南海口571199

出　　处：《黑龙江医学》2021年第21期2351-2353,共3页Heilongjiang Medical Journal

摘　　要：胰腺癌由于其治疗中切除率低、预后差,近来有关其肿瘤免疫治疗在临床治疗中被逐渐认为是一种有效的方法。树突状细胞(Dendritic cells,DC)是机体中尤为重要的抗原体细胞,在肿瘤免疫反应的过程中起着至关重要的作用,DC疫苗在抗胰腺癌免疫治疗作用逐渐受到关注。人体肠道微生态含有细菌种类多且复杂,肠道菌群可能通过调节DC的功能来激活T淋巴细胞,从而介导抗肿瘤免疫反应。本文主要阐明肠道菌-DC瘤苗-胰腺癌细胞三者的联系,为肠道优势菌协同DC疫苗免疫治疗胰腺癌的新方法提供理论依据。Pancreatic cancer immunotherapy has recently been gradually recognized as an effective method in clinical treatment due to its low resection rate and poor prognosis.Dendritic cells(DC)are particularly important antigen-extracting cells in the body.They play a vital role in the process of tumor immune response.The role of DC vaccines in anti-pancreatic cancer immunotherapy has gradually attracted attention.The human intestinal bacteria are diverse and complex.The intestinal flora may activate T lymphocytes by regulating the function of DCs,thereby mediating anti-tumor immune responses.This article mainly clarifies the relationship between intestinal bacteria,DC tumor vaccine and pancreatic cancer cells,and provides a theoretical basis for a new method of intestinal dominant bacteria and DC vaccine immunotherapy for pancreatic cancer.

关 键 词：DC疫苗 肿瘤免疫疗法 胰腺癌 TLR NF-κB 肠道优势菌 

分 类 号：R735.9[医药卫生—肿瘤]